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United KingdomSUMMARY
Liver fibrosis is a common end pathway of any type of chronic
hepatic injury. It is now known that epigenetic mechanisms
including DNA methylation, histone modifications and
non-coding RNAs appear to orchestrate many aspects of liver
fibrogenesis. This review considers recent gains in knowledge
of epigenetic programming in the context of hepatic fibrosis,
which is paving the way to discovery of epigenetic biomarkers
as well as long awaited diagnostic and prognostic tools.
Liver fibrosis arises because prolonged injury combined
with excessive scar deposition within hepatic parenchyma
arising from overactive wound healing response mediated
by activated myofibroblasts. Fibrosis is the common end
point for any type of chronic liver injury including
alcoholic liver disease, nonalcoholic fatty liver disease,
viral hepatitis, and cholestatic liver diseases. Although
genetic influences are important, it is epigenetic mecha-
nisms that have been shown to orchestrate many aspects of
fibrogenesis in the liver. New discoveries in the field are
leading toward the development of epigenetic biomarkers
and targeted therapies. This review considers epigenetic
mechanisms as well as recent advances in epigenetic
programming in the context of hepatic fibrosis. (Cell Mol
Gastroenterol Hepatol 2017;4:125–134; http://dx.doi.org/
10.1016/j.jcmgh.2017.04.007)
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logic outcome of virtually all CLD, usually defined by the
excessive accumulation of fibrous connective tissue in and
around inflamed or damaged tissue.1–3
The liver is made up of many cell types whose compo-
sition as well as phenotype ultimately changes in CLD. It is
now well-documented that cellular phenotype is at least in
part under control of chromatin configuration at key regu-
latory genes; this in turn is governed by epigenetic mecha-
nisms.4 The term epigenetics describes reversible changes in
gene expression that can be inherited through cell division
that do not involve alterations to the underlying DNA
sequence.5 Epigenetic changes occur ubiquitously in all cells
and are most readily observed in our bodies where a single
genome gives rise to numerous different cell types.4The epigenome is influenced by a number of factors
including age, gender, the environment (diet, drug use,
smoking), aswell as the underlying genome through presence
of single nucleotide polymorphisms.6 The epigenome is
governed by at least 3 systems, namely DNA methylation,
histone modifications, and non-coding RNA (ncRNA) medi-
ated gene silencing7–10 (Figure 1). These separate but inter-
acting and overlapping epigenetic mechanisms are currently
considered to initiate and sustain DNA and chromatin mod-
ifications that underpin cellular phenotype by facilitating the
control of gene transcription by sequence-specific tran-
scription factors.10–13 All 3 epigenetic mechanisms regulate
the chromatin structure, modifications, and the initiation of
transcription in amanner that alters the accessibility of genes
to transcription factors and their cofactors that dictate the
rate atwhich a gene is actively transcribed.7–10 Therefore, it is
not surprising that epigenetics has become a research area of
much interest, linking changes in chromatin states to the
cellular phenotype and, in turn, the functioning of an organ.
Large numbers of studies have considered the impact of
epigenetic changes on liver function in health as well as in
disease states. Here we consider the epigenetic mechanisms
involved in the pathogenesis of liver fibrosis as well as
examine recent advancements in the field and discuss new
epigenetic approaches and strategies for the treatment of
liver fibrosis.14
The Epigenetic Code and Mechanisms
Genomic DNA contains all the information that a cell, and
indeed the organism, requires for life. The DNA sequence, or
the genome, is identical in all cells of a particular organism.
However, the epigenome is entirely cell type specific, such
that combination of the above-mentioned 3 epigenetic
mechanisms is carefully defined and maintained to support
the phenotype of that particular cell.4,10,12,13 Therefore,
although the genome of every cell in the body is the same,
the epigenome will govern the phenotype, such that a
Figure 1. Epigenetic mechanisms of heritable gene expression regulation. There are several highly interdependent
epigenetic mechanisms that are important in the control of gene expression, namely DNA methylation (and hydrox-
ymethylation), histone post-translational modifications, and ncRNA-based pathways, including small and long ncRNA species.
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that will differ from that of an adipocyte or a nerve cell.15,16
DNA in a cell is not naked but rather packaged around
histones into a structure known as chromatin. Chromatin is
composed of w146 base pairs of genomic DNA sequence
wrapped around 8 core histones to form the basic unit of
chromatin, the nucleosome. The main functions of chro-
matin are to efficiently package DNA into a reduced volume
such that it can fit into the nucleus of a cell, protect the DNA
structure and sequence, prevent chromosome breakage, and
regulate gene expression as well as DNA replication. Each
nucleosome contains a core of 8 histones (2 copies of H2A,
H2B, H3, and H4), which are small, globular proteins with a
long N-terminal tail that is subject to numerous post-
translational modifications including acetylation, methyl-
ation, phosphorylation, SUMOylation, ubiquitination, or
ADP-ribosylation. A large number of histone-modifying en-
zymes act to carry out more than 60 different possible
modifications within each octamer of histones.The presence of chemical groups on the histones creates
binding sites for specific protein complexes that can pro-
mote either activation or silencing of gene transcription.10
As an example, lysine residues within histones can be
acetylated, which is mediated by histone acetyltransferases
and associated with active gene transcription due to
enhanced recruitment of other chromatin remodelling en-
zymes and prevention of chromatin compaction. Conversely,
gene silencing or repression is frequently associated with
the removal of acetyl groups by histone deacetylases
(HDACs).17 Histone methyltransferases have the ability to
add 1, 2, or 3 methyl groups to lysines or arginines within
histones H3 or H4. The impact of methylation on gene
transcription depends on the specific site of the covalent
modification; for instance, histone 3 lysine 4 trimethylation
causes transcriptional activity, whereas histone 3 lysine 9 or
lysine 27 leads to transcriptionally silent chromatin.10,18,19
Combinations of histone marks therefore provide changes
in chromatin conformation and confer unique biological
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marks, which is also termed the histone code.
Histone modifications do not operate in isolation. They
are tightly interlinked with DNA methylation, the second
epigenetic mechanism. DNA methylation takes place on the
fifth carbon of pyrimidine ring in cytosine nucleotides and
most commonly in cytosine-phospho-guanine (CpG) di-
nucleotides.20 Long stretches of DNA (longer than 200 base
pairs) containing dense (>55%) clusters of CpG sequences
are termed CpG islands. Most human gene promoters
contain 1 or more clusters of CpG islands, mostly found in
unmethylated state, whereas many non-promoter CpGs are
methylated throughout the genome.21,22 Methylation of DNA
is carried out by enzymes called DNA methyltransferases
(DNMTs), which use S-adenosyl methionine as methyl
donor. DNMT family has 5 members, but only 3 of the 5
members have DNMT activity. The DNMT3a and DNMT3b
methylate de novo CpG islands generate new epigenetic
marks.23 DNMT1 maintains DNA methylation status during
the DNA replication, a process that in mammals requires a
protein UHRF1, which is thought to recruit DNMT1 to DNA
replication forks through a unique hemi-methylated CpG-
binding activity.24
DNA methylation is the most studied mechanism of
epigenetic programming and is important in the regulation
of imprinted gene expression as well as silencing the
expression and mobility of transposable elements.25
Genomic methylation patterns are stable, heritable, and
crucial to generate cells from somatic differentiated
cells.26,27 Recently the existence of an oxidative form of the
cytosine, 5-hydroxymethylcytosine has been reported;
5-hydroxymethylcytosine is generated by the Ten Eleven
Translocation (TET) enzyme family that comprises TET1,
TET2, and TET3. TETs present multiple modes of action
either directly or through partners to initiate DNA
demethylation.28
DNA methylation correlates with gene silencing due to
several mechanisms. Methylated CpG islands may promote
condensation of chromatin to states that are unfavorable for
gene expression; they can directly inhibit interaction of DNA
binding proteins to their target sites and provide recogni-
tion signals for the recruitment of methyl-CpG-binding
domain proteins (MeCP2, MBD1-4, and Kaiso) with their
associated complexes.21 However, outside of CpG islands it
is becoming apparent that CpG methylation can correlate
with transcriptionally active genes, particularly when
occurring within the gene body; however, the mechanisms
responsible for this are as yet poorly defined but may relate
to structural requirements for transcription elongation.29
In addition to histone modification and DNA methylation,
RNA molecules are also able to define cellular phenotype
through their gene regulatory functions. It was originally
considered that RNA was a merely intermediary molecule
responsible for transmitting coding information from genes
to proteins, and it was also thought that regions of the
genome that lacked obvious protein-coding sequence were
“junk”. However, advances in molecular biology and high-
throughput genomic techniques provided comprehensive
genomic maps. The ENCODE project revealed that morethan 80% of the genome has biological activity, and only 2%
is transcribed to protein-coding genes. ncRNAs are func-
tional non–protein-coding RNA molecules that are concen-
trated within the nucleus and expressed at lower
concentrations than coding RNAs.30,31 Functional mecha-
nisms of ncRNAs involve epigenetic regulation of gene
expression. The extensive number of ncRNAs transcribed
from the genome and discovered in the last decade has
required detailed classification related to their sizes and
functional mechanisms, which include small nucleolar RNAs,
microRNAs (miRNAs), PIWI-interacting RNAs, small-
interfering RNAs, enhancer RNAs, and long non-coding
(lncRNAs). In this review we focus our attention toward
miRNAs because they have been the most extensively
studied of all ncRNAs in the context of liver disease.32–34
miRNAs are single-stranded short ncRNA molecules
(20–24 nucleotides) that post-transcriptionally regulate
gene expression by several mechanisms including repres-
sion of translation or mRNA cleavage and degradation (by
binding to the 30-untranslated regions of mRNA).35,36
miRNAs are able to epigenetically silence expression of genes
in a wide variety of biological pathways including proliferation,
apoptosis, and cellular signalling and thus are thought to
play an important role in a variety of human diseases.
Modulation of DNA Methylation After
Liver Damage
Aberrant DNA methylation patterns are associated with
inappropriate gene repression and human disease processes
including fibrosis.37–39 Komatsu et al40 reported a crucial
DNA hypomethylation in fibrogenic genes from the onset of
liver fibrosis by using an in vivo early-stage animal model of
liver fibrosis. Moreover, an in vitro approach using quies-
cent and early culture-activated hepatic stellate cells (HSCs)
showed a global demethylation during activation of HSCs.41
Genome-wide analysis performed by the van Grunsven
group identified an integrative concordance between
promoter methylation landscapes and gene expression in
culture-activated human HSCs.42
DNA methylation in cells is in large part interpreted via
binding of methyl binding proteins, which in turn recruit
transcriptional repressor complexes to the sites of DNA
methylation. During transdifferentiation, HSCs start to ex-
press MECP2, which along with MBD1, MBD2, MBD3, and
MBD4 comprises a family of nuclear proteins related by the
presence of amethyl-CpG binding domain.43–46 MECP2 is able
to repress transcription frommethylated gene promoters, and
it is therefore considered to be a transcriptional repressor that
has been shown to mediate epigenetic silencing of the
peroxisome proliferator activated receptor gamma (PPARg)
gene, a master transcriptional regulator of the adipogenic,
quiescent, and non-fibrogenic phenotype of the HSC.43,44,47 To
confirm functional association of DNA methylation with liver
fibrosis, our group reported that transdifferentiation of the
HSC to the profibrogenic myofibroblast phenotype is sup-
pressed by the DNMT inhibitor 50-aza-deoxycytidine.44
In addition to its repressive role, MeCP2 has been
reported to also exert transcriptional activation, although
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elucidated.48 In relation to this function, we have shown that
MeCP2 positively regulates expression of the histone
methyltransferase ASH1 during HSC transdifferentation.49
ASH1 regulates attachment of methyl group to lysine 4 on
histone H3 (H3K4), thus promoting transcriptional activ-
ity.50 In activated HSCs, ASH1 is required for expression of
classic profibrogenic genes collagen I, tissue inhibitor of
metalloproteinase-1, and transforming growth factor b1.49
Taken together, MeCP2 appears to regulate repression of
antifibrogenic genes while also inducing expression of
positive regulators of profibrogenic genes such as ASH1.
Mice lacking MeCP2 are therefore resistant to developing
fibrosis in models of chronic lung and liver damage, which
coupled with the ability of MeCP2 to stimulate upregulation
of multiple fibrogenic genes indicates its potential to func-
tion as a bona fide “core” master epigenetic regulator of
myofibroblast phenotype and fibrogenesis.43 As such, it will
now be important to reveal finer details of MeCP2 mecha-
nism of actions in hepatic myofibroblasts, which may
include regulation of gene expression via direct
me-CpG-dependent transcriptional processes or by indirect
post-transcriptional mechanisms.
Development of fibrosis is associated with changes in the
expression of enzymes that regulate DNA methylation and
hydroxymethylation.51 We have recently shown that
expression of the maintenance DNA methyltransferase
DNMT1 and of the de novo methyltransferases DNMT3a and
3b tend to increase in fibrotic liver.51 By contrast, hepatic
expression of the TET demethylase enzymes is
downregulated in chronic liver disease.51 Associated with
these changes in expression of DNA methylation
regulators were global changes in 5-methylcytosine and
5-hydroxymethylcytosine that are indicative of genome-
wide alterations in gene expression. The mechanisms by
which methylome relandscaping promotes genome-wide
resetting of gene transcription in fibrosis are yet to be
defined but may involve alterations in the recruitment of
chromatin remodelling complexes that silence gene
expression. Another possibility is that TET-regulated con-
version of 5-methylcytosines to 5-hydroxymethylcytosines
may result in transcriptional activation or an increase in
transcriptional elongation.52,53 It is anticipated that the
recent development of Cas9-targeting protocols for the
experimental manipulation of sequence-specific DNA
methylation will dramatically improve our understanding of
the mechanistic relationships between methylome relands-
caping and gene expression.54,55
Advancing on these studies, we have identified genome-
wide sequence-specific changes in 5-methylcytosine and
5-hydroxymethylcytosine marks occurring during HSC
transdifferentiation that were accompanied by alterations in
the expression of DNMTs and TET enzymes.51 The next
challenge will be to establish whether these alterations in
methylation at specific CpG sites result in alterations in gene
expression that impact on HSC fate and function. Further-
more, experimental manipulation of the activities of DNMTs
or TETs at fibrogenic genes may offer new therapeutic
avenues. Clearly, such approaches would have to be carriedout by using a cell type–specific and targeted approach,
because systemic epigenetic therapy is likely to have many
unwanted side effects.
The interrogation of DNA methylome signatures in hu-
man liver can distinguish patients with different stages of
nonalcoholic fatty liver disease (NAFLD) or fibrosis.56–58
Hence, determining the DNA methylation status of specific
CpG sites in patient tissues may provide useful biomarkers
to define disease diagnosis and prognosis. However, these
approaches have so far been unattractive because they
relied on analysis of tissue provided by liver biopsy, an
invasive procedure that carries a number of procedure-
associated risks.58,59 Advancing on studies carried out on
liver biopsy tissue, we have recently published that quan-
tification of DNA methylation from circulating cell-free DNA
isolated from patient plasma has the potential to stratify
fibrosis grade with high accuracy.60 Specifically, we
demonstrated that differential DNA methylation status at
the PPARg promoter in cell-free DNA in plasma can distin-
guish between patients with mild versus severe fibrosis in
the context of NAFLD.60 In this context, it is thought that
dying hepatocytes release degraded genomic DNA into
systemic circulation, which can be picked up peripherally by
isolation from plasma. The level of DNA methylation at
particular CpGs within the PPARg promoter can therefore
reflect the changes in methylation present in hepatocytes;
thus, it is a proxy measurement of changes within the liver
without the need for a needle biopsy.
Dysregulation of Histone Code in
Liver Disease
The number of studies pinpointing the regulatory role of
histone modifications in liver injury has increased in the last
decade, with most relating to changes in histone acetylation
due to pharmacologic use of HDAC inhibitors.61,62 HDAC
inhibitors have been shown to reverse myofibroblast dif-
ferentiation and exert antifibrogenic effects in fibrosis-
related pathologies such as pulmonary, dermal, or renal
fibrosis.63–66 Class I and II HDAC inhibitors have received
most of the attention in the liver field, probably owing to
their antiproliferative properties and ability to induce cell
death via deacetylation of multiple HDAC substrates.17 As an
example, the class I inhibitor largazole can induce apoptosis
and suppress proliferation of HSC by increasing the acety-
lation of histones H3 and H4.67 Likewise, valproate sodium,
a broad class I and II HDAC inhibitor, exerts its anti-
fibrogenic properties by inhibiting the expression of
collagen 1A1 and transforming growth factor b1 without
causing cytotoxic damage.68 Valproate sodium has also been
shown to block myofibroblast differentiation and fibro-
genesis in mouse models of liver fibrosis.69 The mechanism
of HDAC1 effects in myofibroblasts at least in part relates to
anti-inflammatory and antifibrogenic action via recruitment
to genes such as Ccl2, Cxcl10, Gm-csf, and Mmp13.70 How-
ever, the majority of HDAC inhibitors lack target or cell-
specific activities, with none currently tested in human
clinical trials. Consequently, although there is interest in the
development of HDAC inhibitors as antifibrogenic agents,
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effects and the design of more target-selective inhibitors as
well as test their efficacy in patients.
Another means of regulating histone acetylation is via
inhibition of bromodomain binding. Bromodomains are
110-kDa domains contained within a number of different
proteins that serve as “readers” of lysine acetylation. These
domains have been predominantly studied in the context of
the bromodomain and extra-terminal domain family, most
notably BRD4, which is critical for binding to hundreds of
enhancers associated with genes involved in multiple pro-
fibrotic pathways in HSCs.71 Targeted inhibition of BRD4
through use of the JQ1 drug has been shown to block HSC
activation and proliferative capacity, thus limiting fibrosis
in vivo.71
HSC transdifferentiation is in part orchestrated by the
histone methyltransferases (EZH2 and ASH1) downstream
of the master epigenetic regulator MeCP2. EZH2 is induced
at the protein level during the initiation stage of HSC
transdifferentiation and is recruited to the PPARg gene
where it promotes accumulation of the repressive chro-
matin signature H3K27me3; this event is required to
reprogram the quiescent HSC transcriptome to myofibro-
blast phenotype.43 In parallel, ASH1 is recruited to the
promoter regions of alpha-smooth muscle actin, collagen
1A1, tissue inhibitor of metalloproteinase-1, and trans-
forming growth factor b1 genes, facilitating a transcriptional
active state.49 To increase the knowledge of how these en-
zymes regulate liver fibrosis, it will be interesting to develop
specific conditional knockout mice along with the design of
specific drugs that target their activities. For instance, the
active compounds of the herbal preparation Yang-Gan-Wan
can attenuate liver fibrosis progression and HSC trans-
differentiation by repressing the MeCP2-EZH2 axis.72 More
recently we have used an HSC-targeted nanoparticle
approach for selectively delivering the EZH2 inhibitor
30deazaneplanocin A to these cells in vivo and shown that
this achieves suppression of the progression of pre-
established liver fibrosis in mice.
Liver-damaging agents can also dysregulate chromatin
structure. Several studies have described the epigenetic
mechanisms involved in alcoholic liver injury, which entail
action of reactive oxygen species on several histone mod-
ifications.73–76 Alcohol and its metabolites can promote
transdifferentiation of HSC either directly or through pro-
fibrogenic cytokines expressed by hepatocytes. HDAC6
function is compromised in ethanol-treated HSCs, which
leads to modifications in microtubule dynamics.77 A study
performed by Kim and Shukla78 reported that alcohol
increased acetylation of H3K9 in a dose- and time-
dependent basis in rat HSCs. Multiple histone methyl-
transferases including MLL1 are induced in ethanol-exposed
HSCs; these changes are associated with enrichment of the
transcriptional stimulatory H3K4 methylation mark at
numerous genes.79 Illuminating the mechanisms by which
alcohol directly influences the HSC epigenome is important
because it will improve our understanding of how alcohol
promotes fibrosis and potentially reveal new therapeutic
targets. Two recent studies performed on a genome-widesurvey basis suggest that genes activated in the livers of
patients with NAFLD strongly correlate with histone modi-
fication marks.80,81
Small Non-coding RNAs as
Epigenetic Intermediaries
The role of miRNAs in liver pathophysiology has been
covered in excellent reviews elsewhere.32,82 miRNAs
contribute to the various pathologic stages of liver disease
and also participate in the control of HSC transdifferentiation,
making them potential biomarker and therapeutic tools.83
The number of publications describing the role of miRNAs
in liver fibrosis has grown exponentially in the last decade,
therefore creating a list of liver profibrotic (miR-21, -221/
222, -181b, or -150) and antifibrotic (miR-29b, -101, -122, or
-214-3p) miRNAs.84 Recent advances in comparative
bioinformatics have revealed an extensive list of miRNAs
associated with quiescent state and myofibroblastic states of
HSC. By using the Mercury array platform, upregulation of 12
miRNAs (miR-874, -29c*, -501, -349, -325-5p, -328, -138,
-143, -207, -872, -140, and 193) and downregulation of 9
miRNAs (miR-341, -20b-3p, -15b, -16, -375, -122, -146a, -92b,
and -126) have been associated with transdifferentiation of
rat HSCs.85 miRNA profiles were also determined in quies-
cent, partially activated, and activated rat HSCs by using the
Agilent microarray platform. Chen et al86 confirmed the
increased expression of miR-221, -143, and-145 and
the downregulated expression of miR-335 and -150 during
the HSC activation. Finally, the latest next-generation
sequencing by using Ago2 immunoprecipitation plus use of
the deep sequencing Illumina platform has identified novel
miRNA targets in human and rat HSCs.87 Neuronal-specific
miRNAs were identified in myofibroblastic HSC, with mir-9,
-125b, and -128 being upregulated and found to be regu-
lating chemokine networks.87 Moreover, the Sancho-Bru
group recently reported an integrative gene expression and
miRNA profiling in human HSC.88 By using the miRNA Taq-
man array, they identified novel miRNA-target/mRNA inter-
action networks involved in HSC activation and highlighted
the downregulation of miR-192 as a key event in the early
phase of HSC transdifferentiation.88
Circulating microRNAs may offer a biologically stable
blood-based biomarker tool for detection and stratification
of liver disease. Circulating miRNAs were discovered as
stable miRNAs secreted extracellularly to different biofluids
through extracellular boundary to Ago2 or protected against
RNase activity when internalized in exosomes (cell-derived
extracellular vesicles).89,90 In relation to this, alterations in
the expression of cell-free circulating miRNAs have been
associated with progression of disease in NAFLD and alco-
holic liver disease.91,92 Increasing serum levels of miR-196
and the liver regulator miR-122 have been found in
NAFLD/nonalcoholic steatohepatitis, as well as in alcoholic
liver disease.93,94 Moreover, upregulation of miR-571 and
reduction of miR-652 in serum samples from CLD patients
highlighted the cellular-compartment specific roles these
circulatory miRNA infer on the fibrogenic and inflammatory
processes.95 Therefore, future identification of circulating
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homeostasis and disease prognosis.Heritability of Liver Fibrosis
Recent years have seen a major advancement in the field
of transgenerational epigenetic inheritance of traits. These
advances show existence of phenotypic adaptation of
species in response to environmental pressures and
cues. Although described studies cover several organ sys-
tems ranging from olfactory perception to increased sus-
ceptibility to depressive tendencies, some of the reports
concern liver disease.
Our lab has shown that ancestral history of liver fibrosis
in male rats leads to suppression of wound healing
responses in offspring in at least 2 subsequent genera-
tions.56 The mechanism of adaptation in this study involves
remodelling of DNA methylation in key fibrotic genes in the
liver as well as sperm.56 Importantly, similar remodelling
has been observed in human NAFLD liver tissues, where
DNA methylation signature can discern mild from severe
fibrosis, whereas a separate study also confirms existence of
altered DNA methylation signatures in human ALD livers.58
Although there is no existing study in humans to confirm
the presence of transgenerational epigenetic inheritance, a
recent study carried out in monozygotic and dizygotic twins
delineated the presence of epigenetic mechanisms that
contribute to the heritable component of NAFLD.96,97 This
study interrogates epigenetic mechanisms that could
account for discordance in the presence or absence of
NAFLD in pairs of individuals who are genetically highly
similar. By using liver magnetic resonance imaging proton-
density fat fraction to quantify fat content and miR
profiling of their serum, the study identifies a panel of 10
miRs that differentiated the twin with NAFLD from the twin
without the disease. Of those, miR-331-3p and miR-30c
were both highly correlated with each one and found to
be heritable, suggesting involvement in a common mecha-
nistic pathway, as shown by interactome analysis that
highlights 7 common target genes.98
Evidence that epigenetic mechanisms can be inherited
has also come from a study that compares spermatozoa
from lean versus obese patients and outlines differences in
DNA methylation patterns and small ncRNA content of
sperm. Importantly, these epigenetic signatures were
remodelled after bariatric surgery and subsequent weight
loss in the obese patients, suggesting that mechanisms likely
exist to ensure inheritance of metabolic traits by the prog-
eny, which can be passed on in sperm.99 These studies
provide exciting novel insights into heritability of traits and
their intergenerational plasticity. However, much more
work is required to begin to appreciate the extent to which
epigenetics can explain complex human disease.Conclusion
The latest studies highlight the regulatory effect that
epigenetic modifications exert in the liver fibrosis process;
however despite many published data, epigenetics are farfrom being elucidated.100,101 Next-generation sequencing,
along with advances in molecular technologies such as
CRISPR/Cas9, provide the tools that can, in time, expand our
current knowledge of the liver epigenome. Defining epige-
netic signatures through the stages of liver disease could
provide novel opportunities to develop therapies to specific
targets. However, these developments will first have to
grasp the complexities of interaction between histone code,
DNA methylation, and ncRNA in a single type of liver cell,
followed by interactions between numerous cell types
within the liver, all of which will have their exquisitely
specific epigenome. These epigenomes are highly plastic and
responsive to the cues from their microenvironment and
macroenvironment. Therefore, the second major task will be
to understand which of these epigenetic signatures is “pre-
set” and hard-wired into developmental inheritance of a
particular phenotype versus epigenetic signatures that
evolve because of environmental pressure as well as pres-
sures created by the disease process. Furthermore, the
environmental epigenetic signatures need to be distin-
guished from the epigenetic marks associated with ageing,
which may introduce a third layer of complexity because the
latter are likely to be predetermined and potentially more
difficult to remodel. This is an area that is fast developing,
and future studies are eagerly anticipated. The diagnostic,
prognostic, and therapeutic possibilities that may emerge
from greater understanding of epigenetic mechanisms and
their operation in liver disease promise to deliver exciting
advances in personalized medicine.
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